Neurofibromatoses Type I (Von Recklinghausen s Disease) - Pipeline Review, H1 2018

  • ID: 4576050
  • Drug Pipelines
  • 49 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Array BioPharma Inc
  • AstraZeneca Plc
  • Pfizer Inc
  • MORE
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline Review, H1 2018, provides an overview of the Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders) pipeline landscape.

Neurofibromatosis type 1 (NF1), also called von Recklinghausen's disease, is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules and pheochromocytoma. Treatment includes pain medications, surgery, chemotherapy and radiation therapy.

Report Highlights:

This latest pipeline guide Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III and Phase II stages are 1 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Array BioPharma Inc
  • AstraZeneca Plc
  • Pfizer Inc
  • MORE
Introduction

Report Coverage

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Overview

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Companies Involved in Therapeutics Development

Array BioPharma Inc

AstraZeneca Plc

Pfizer Inc

SpringWorks Therapeutics LLC

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Drug Profiles

binimetinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-0325901 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

selumetinib sulfate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sirolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Neurofibromatoses Type I - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Dormant Projects

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Product Development Milestones

Featured News & Press Releases

Dec 10, 2012: Study Identifies Targeted Molecular Therapy For Untreatable NF1 Tumors

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Array BioPharma Inc, H1 2018

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by AstraZeneca Plc, H1 2018

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Pfizer Inc, H1 2018

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by SpringWorks Therapeutics LLC, H1 2018

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Array BioPharma Inc
  • AstraZeneca Plc
  • Pfizer Inc
  • SpringWorks Therapeutics LLC
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll